A5039800393- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Metabolism, Diabetes, and Cancer
- PI3K/AKT/mTOR signaling in cancer
- Cancer Risks and Factors
- Viral-associated cancers and disorders
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Hematopoietic Stem Cell Transplantation
- Cancer-related Molecular Pathways
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Tumors and Oncological Cases
- Childhood Cancer Survivors' Quality of Life
Institut Jules Bordet
2020-2024
Université Libre de Bruxelles
2020-2024
University of Naples Federico II
2013-2024
Federico II University Hospital
2023-2024
Azienda Ospedaliero-Universitaria Careggi
2021-2024
Azienda Ospedaliera Universitaria Pisana
2015-2023
Associazione Italiana Di Oncologia Medica
2023
Baylor College of Medicine
2017-2021
University of Pisa
2018-2020
Ospedale Santa Chiara
2015-2019
There are limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer, especially patients treated with endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitors.A pooled analysis individual patient-level from MONARCH 2 and 3 trials was performed. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 overweight (25-29.9 obese (≥30 kg/m2) divided treatment groups: abemaciclib ET vs placebo ET. The...
Background. The event-free survival for pediatric leukemia in low-income Countries is much lower than high-income countries. Late diagnosis, which regarded as a contributing factor, may be due to "parental" or "medical" delay. Procedures. present study analyses determinants of lag time from first symptoms diagnosis leukemia, comparing (0-16 years old) patients two referral centers, one Nicaragua and Italy. An observational retrospective was conducted assess factors influencing the diagnosis....
Abstract Data from 423 human epidermal growth factor receptor 2‐negative (HER2−), hormone receptor‐positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian centers analyzed for treatment outcomes. Overall, 158 in first line 265 second/later lines. We observed 19 complete responses 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) clinical benefit 52.7% CI,...
Bevacizumab in combination with taxanes HER2-negative metastatic breast cancer (MBC) patients has shown improved progression-free survival (PFS), despite the lack of clear overall (OS) benefit. We performed a retrospective analysis to evaluate impact paclitaxel-bevacizumab and maintenance therapy bevacizumab (BM) endocrine (ET) real-world practice. identified 314 MBC treated 12 centers. Overall, median PFS OS were 14 40 months, respectively. Among 254 potentially eligible for BM, 183...
The main functions of natural killer (NK) cells are early protection against viruses or tumor and production cytokines that regulate immune functions. present study assessed the role different NK subsets in exerting graft-versus-leukemia effects recipients human leukocyte antigen (HLA) haploidentical hematopoietic transplants monitored for first time CD3–/CD56– lymphocyte expansion. expressed cell-associated molecules, such as CD16, NKp46, NKp30, CD244 (2B4), CD161, cell immunoglobulin-like...
BackgroundAnticancer drugs can interact with the tumour microenvironment and their effects could be exploited to favour anticancer immune response. Eribulin contributes vasculature remodelling transforming growth factor β (TGF-β) modulation in experimental models humans. We performed a prospective, translational, exploratory analysis of levels circulating cytokines at different time points patients metastatic breast cancer treated eribulin.MethodsTGF-β, necrosis α, vascular endothelial...
The evidence emerged from the TOURANDOT trial encourages evaluating role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data a subgroup these larger cohort previously assessed for outcomes. Patients were included present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall study population subgroups...
Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite this most of these tumors develop resistance to therapy due specific gene mutations or alterations in expression. Understanding the mechanisms could be a useful tool order identify combinations drugs that elude and allow better response treated patients. Twelve primary biopsies Her2+/hormone receptor negative (ER-/PgR-) cancer patients were selected based on neoadjuvant with their whole exome was sequenced...
Abstract Background: The CDK4/6-inhibitor palbociclib (Palbo) in combination with endocrine therapy (ET) substantially improves progression-free survival compared to ET alone. However, almost all initial responders eventually develop resistance and relapse. Delineating the early adaptive signaling mechanisms underlying CDK4/6 inhibition is therefore crucial identify new biomarkers therapeutic targets enhance efficacy of Palbo improve patient outcome. Materials Methods: MCF7 parental (P)...
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival first-line (mPFS1) was 12 months. Pertuzumab as conferred longer mPFS1 compared other treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS second-line (mPFS2) 7 no difference subtype,...
Abstract Purpose: The mTOR complex C1 (mTORC1) inhibitor everolimus in combination with the aromatase exemestane is an effective treatment for patients hormone receptor—positive (HR+), HER2-negative (HER2−), advanced breast cancer (HR+/HER2− aBC). However, can cause hyperglycemia and hyperinsulinemia, which could reactivate PI3K/protein kinase B (AKT)/mTORC1 pathway induce tumor resistance to everolimus. Experimental Design: We conducted a multicenter, retrospective, Italian study...